Targeting neuroendocrine prostate cancer: molecular and clinical perspectives
Neuroendocrine prostate carcinoma, either co-present with the local adenocarcinoma disease or as a result of transdifferentiation later in time, was described as one major process of emerging resistance to androgen deprivation therapies, and at the clinical level it is consistent with the developmen...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2015-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00006/full |
| _version_ | 1818542343948599296 |
|---|---|
| author | Panagiotis J Vlachostergios Christos N Papandreou |
| author_facet | Panagiotis J Vlachostergios Christos N Papandreou |
| author_sort | Panagiotis J Vlachostergios |
| collection | DOAJ |
| description | Neuroendocrine prostate carcinoma, either co-present with the local adenocarcinoma disease or as a result of transdifferentiation later in time, was described as one major process of emerging resistance to androgen deprivation therapies, and at the clinical level it is consistent with the development of rapidly progressive visceral disease, often in the absence of elevated serum prostate-specific antigen level. Until present, platinum-based chemotherapy has been the only treatment modality, able to produce a fair amount of responses but of short duration. Recently, several efforts for molecular characterization of this lethal phenotype have resulted in identification of novel signaling factors involved in microenvironement interactions, mitosis, and neural reprogramming as potential therapeutic targets. Ongoing clinical testing of specific inhibitors of these targets, for example Aurora kinase A inhibitors, in carefully selected patients and exploitation of expression changes of the target before and after manipulation is anticipated to increase the existing data and facilitate therapeutic decision making at this late stage of the disease when hormonal manipulations, even with the newest androgen-directed therapies are no longer feasible. |
| first_indexed | 2024-12-11T22:20:50Z |
| format | Article |
| id | doaj.art-97a08a8e7a714a499097b5326fcc57d8 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T22:20:50Z |
| publishDate | 2015-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-97a08a8e7a714a499097b5326fcc57d82022-12-22T00:48:26ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2015-02-01510.3389/fonc.2015.00006123610Targeting neuroendocrine prostate cancer: molecular and clinical perspectivesPanagiotis J Vlachostergios0Christos N Papandreou1Lutheran Medical CenterUniversity of Thessaly, School of Health Sciences, Faculty of Medicine, University Hospital of LarissaNeuroendocrine prostate carcinoma, either co-present with the local adenocarcinoma disease or as a result of transdifferentiation later in time, was described as one major process of emerging resistance to androgen deprivation therapies, and at the clinical level it is consistent with the development of rapidly progressive visceral disease, often in the absence of elevated serum prostate-specific antigen level. Until present, platinum-based chemotherapy has been the only treatment modality, able to produce a fair amount of responses but of short duration. Recently, several efforts for molecular characterization of this lethal phenotype have resulted in identification of novel signaling factors involved in microenvironement interactions, mitosis, and neural reprogramming as potential therapeutic targets. Ongoing clinical testing of specific inhibitors of these targets, for example Aurora kinase A inhibitors, in carefully selected patients and exploitation of expression changes of the target before and after manipulation is anticipated to increase the existing data and facilitate therapeutic decision making at this late stage of the disease when hormonal manipulations, even with the newest androgen-directed therapies are no longer feasible.http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00006/fulltargeted therapyCastration-resistantAndrogen independentneuroendocrine prostate cancersmall cell prostate carcinoma |
| spellingShingle | Panagiotis J Vlachostergios Christos N Papandreou Targeting neuroendocrine prostate cancer: molecular and clinical perspectives Frontiers in Oncology targeted therapy Castration-resistant Androgen independent neuroendocrine prostate cancer small cell prostate carcinoma |
| title | Targeting neuroendocrine prostate cancer: molecular and clinical perspectives |
| title_full | Targeting neuroendocrine prostate cancer: molecular and clinical perspectives |
| title_fullStr | Targeting neuroendocrine prostate cancer: molecular and clinical perspectives |
| title_full_unstemmed | Targeting neuroendocrine prostate cancer: molecular and clinical perspectives |
| title_short | Targeting neuroendocrine prostate cancer: molecular and clinical perspectives |
| title_sort | targeting neuroendocrine prostate cancer molecular and clinical perspectives |
| topic | targeted therapy Castration-resistant Androgen independent neuroendocrine prostate cancer small cell prostate carcinoma |
| url | http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00006/full |
| work_keys_str_mv | AT panagiotisjvlachostergios targetingneuroendocrineprostatecancermolecularandclinicalperspectives AT christosnpapandreou targetingneuroendocrineprostatecancermolecularandclinicalperspectives |